Rosiglitazone, a drug originally developed to treat type 2 diabetes, was approved by the United States Food and Drug Administration (FDA) in 1999 under the name Avandia. The drug has already been suspended in Europe and restricted in use in the US due to concerns about how it may affect heart health, but the strength of the data was in question. Now a new study has found that there is a 33% higher risk of heart attack with this drug. Read more